Availability and Challenges of GLP-1 and GLP-1 + GIP Medications Offered by Maximus
Maximus provides GLP-1 medications to support various health protocols. However, there are specific challenges and limitations regarding the availability of GLP-1 and GLP-1 + GIP medications in certain states. Below is a detailed overview of the current situation:
GLP-1 + GIP Protocols
The GLP-1 + GIP protocol is no longer available for new sign-ups as of May 16, 2025. This change is due to updated offerings and a shift in focus to the GLP-1 protocol, which includes Microdoses, Starter Packs, and Regular Plans. Additionally, supply limitations and fulfillment challenges, influenced by new regulations, have made it difficult to ensure continued access to the GLP-1 + GIP protocol.
State-Specific Availability and Restrictions
Texas, Alabama, and Mississippi
Maximus is temporarily unable to provide GLP-1 + GIP medications in Texas (TX), Alabama (AL), and Mississippi (MS) due to pharmacy limitations. The company is actively working to partner with a new pharmacy that can fulfill GLP-1 protocols in these states. In the meantime, affected patients have the option to temporarily cancel their subscriptions and reactivate them once service resumes.
Louisiana
Maximus is unable to offer GLP-1 therapy in Louisiana due to regulatory and operational requirements.
Alabama
Maximus does not prescribe GLP-1 medications in Alabama due to state regulations.
Customer Options During Service Interruptions
For patients affected by temporary service interruptions, Maximus offers the option to:
Temporarily cancel their subscriptions.
Reactivate their subscriptions once the service resumes in their state.
This ensures that patients can manage their subscriptions flexibly while Maximus resolves the underlying challenges.
Regulatory and Supply Chain Challenges
The availability of GLP-1 and GLP-1 + GIP medications is influenced by:
Regulatory Requirements: State-specific regulations impact the ability to prescribe and fulfill these medications.
Supply Chain Limitations: Challenges in sourcing and distributing medications have led to temporary unavailability in certain regions.
Maximus is committed to addressing these challenges by partnering with new pharmacies and adapting its offerings to meet regulatory and operational requirements.
For further updates on the availability of GLP-1 and GLP-1 + GIP medications, please contact Maximus customer support or visit the official website.